Kura Oncology, Inc. is a United States-based company, which is engaged in developing precision medicines for cancer. The Company's development programs target cancers, including lung, colorectal, thyroid and pancreatic cancers, as well as blood cancers, such as lymphoma and leukemias. Its product pipeline includes small molecule drug candidates, which include Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Tipifarnib is an inhibitor of protein farnesylation and indicated for the treatment of Harvey rat sarcoma viral oncogene homolog (HRAS) mutant tumors. Tipifarnib is indicated for the treatment of peripheral T-cell lymphoma. ERK inhibitor program includes a set of compounds, including its lead candidate KO-947 indicated for the treatment of melanoma, lung and pancreatic cancers. Menin MLL inhibitor program a set of orally available, small molecule compounds, indicated for the treatment of mixed lineage leukemias.